Back to Search
Start Over
Immune Checkpoint Inhibitors in Patients with Recurrent Hepatocellular Carcinoma after Liver Transplantation: A Case Report and Literature Review
- Source :
- Current Cancer Drug Targets. 20:720-727
- Publication Year :
- 2020
- Publisher :
- Bentham Science Publishers Ltd., 2020.
-
Abstract
- Background: Immune checkpoint modulators, such as the programmed death protein-1 (PD-1)/programmed death ligand-1 (PD-L1) inhibitor, cytotoxic T-Lymphocyte-associated antigen 4 (CTLA-4) inhibitor have been investigated with encouraging results for hepatocellular carcinoma (HCC). However, the safety of this strategy in patients with previous liver transplantation (LT) is not well studied. Objective: To explore the safety and feasibility of immune checkpoints inhibitors in recurrent and metastatic HCC patients on a background of LT. Methods: A case of recurrent, refractory, metastatic HCC after LT, where PD-1 inhibitor was initiated, was described and related literature was reviewed. Results: There was complete remission in lung metastases and the partial radiological response of metastatic retroperitoneal lymph node to the drug with no liver graft rejection after 13 cycles of PD- 1 inhibitor injection. PD-1inhibitor, at least in this patient, was verified to play an important role in controlling tumor progression and prolonging patient survival. Conclusions: This novel drug might be a useful method to allow doctors to guarantee a better chance for long-term survival in recurrent, metastatic HCC patients with the previous LT. However, it should be used with caution in allograft recipients due to the risk of acute graft rejection, further larger, prospective studies are needed to determine optimal immunomodulatory therapy to achieve optimal anti-tumor efficacy with transplant liver preservation.
- Subjects :
- Adult
Graft Rejection
Male
0301 basic medicine
Oncology
Cancer Research
medicine.medical_specialty
Carcinoma, Hepatocellular
Adolescent
medicine.medical_treatment
Liver transplantation
Immunomodulation
Young Adult
03 medical and health sciences
Fatal Outcome
0302 clinical medicine
Immune system
Antigen
Internal medicine
Drug Discovery
medicine
Humans
Immune Checkpoint Inhibitors
Liver preservation
Aged
Pharmacology
business.industry
Liver Neoplasms
Middle Aged
medicine.disease
Recurrent Hepatocellular Carcinoma
Immune checkpoint
Liver Transplantation
Treatment Outcome
030104 developmental biology
Tumor progression
030220 oncology & carcinogenesis
Hepatocellular carcinoma
Female
Neoplasm Recurrence, Local
business
Subjects
Details
- ISSN :
- 15680096
- Volume :
- 20
- Database :
- OpenAIRE
- Journal :
- Current Cancer Drug Targets
- Accession number :
- edsair.doi.dedup.....8f000d52102f946fce87a8413a957058